New TB vaccines show limited effectiveness in clinical trial
臨床試驗顯示新型肺結核疫苗效力有限
Tuberculosis (TB) remains a major global health challenge, causing millions of cases and deaths every year.
結核病（TB）仍是一項重大的全球健康挑戰，每年造成數百萬例病例和死亡案例。
Scientists have long sought an improved vaccine to replace or supplement the century-old BCG vaccine, which works well for children but offers limited protection for adults.
科學家長期以來一直在尋求改良型疫苗，以取代或補充擁有百年歷史的卡介苗（BCG），該疫苗對兒童效果顯著，但對成人的保護力有限。
A significant recent study, the PreVenTB trial, examined two new vaccine candidates, VPM1002 and Immuvac.
一項重大的近期研究——「PreVenTB」試驗，檢測了兩種新型疫苗候選物VPM1002和Immuvac。
While these vaccines were proven safe, they unfortunately did not show significant protection against standard pulmonary TB in the general population.
雖然這些疫苗被證明是安全的，但遺憾的是，牠們並未在一般人口中對標準肺結核病顯示出顯著的保護效果。
However, the study provided some encouraging news: VPM1002 showed success in preventing extrapulmonary TB, and preliminary data suggests it might be particularly effective in children aged 6 to 14.
然而，該研究提供了一些令人振奮的消息：VPM1002在預防肺外結核病方面表現成功，且初步數據表明，它對6至14歲的兒童可能特別有效。
Interestingly, the researchers found that nutrition plays a key role, as vaccine effectiveness was lower in individuals who were underweight.
有趣的是，研究人員發現營養扮演著關鍵角色，因為營養不良個體的疫苗效力較低。
Moving forward, experts suggest that instead of a universal vaccine, we may need a stratified approach, combining vaccination with nutritional support and targeting specific age groups or high-risk demographics.
展望未來，專家建議我們需要的或許不是一種普及型疫苗，而是一種分層策略，即將疫苗接種與營養支援相結合，並針對特定年齡層或高風險族群進行防護。
While these results are a reminder of the complexity of TB research, the global effort to end this disease continues with other promising candidates currently in development.
雖然這些結果提醒我們結核病研究的複雜性，但終結此疾病的全球努力仍在持續，其他有前景的候選物目前正在研發中。
